ETFChannel.com
GBT Description — Global Blood Therapeutics Inc

Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601.

Company Name: 
Global Blood Therapeutics Inc
Website: 
www.globalbloodtx.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding GBT: 
31
Total Market Value Held by ETFs: 
$619,591,510.16
Total Market Capitalization: 
$4,567,000,000
% of Market Cap. Held by ETFs: 
13.57%
 ETF   GBT Weight   GBT Amount 
 VTI   0.01%   $131,215,871         
 VB   0.10%   $112,115,408         
 IWM   0.20%   $96,104,423         
 XBI   1.13%   $76,951,254         
 VBK   0.25%   $66,476,700         
 VXF   0.07%   $53,924,405         
 IWO   0.38%   $34,037,429         
 VHT   0.08%   $14,264,830         
 VTWO   0.18%   $10,025,196         
 ITOT   0.01%   $4,746,182         
List of all 31 ETFs holding GBT »
Quotes delayed 20 minutes

Email EnvelopeFree GBT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Hold (2.47 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts Forecast:
GBT Price Target

Based on data provided by Zacks Investment Research via Quandl.com

ETFs Holding GBT | Global Blood Therapeutics Inc | ETF Channel | www.ETFChannel.com

Copyright © 2010 - 2022, All Rights Reserved Nothing in ETF Channel is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and ETF videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact ETF Channel; Meet Our Editorial Staff.